Literature DB >> 23503422

PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine.

Evette S Radisky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23503422      PMCID： PMC3739227          DOI： 10.1038/aja.2013.14

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  14 in total

1.  What are the hallmarks of cancer?

Authors:  Yuri Lazebnik
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

2.  -Omics and cancer biomarkers: link to the biological truth or bear the consequences.

Authors:  Lance A Liotta; Emanuel F Petricoin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-18       Impact factor: 4.254

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

Review 4.  Cancer biomarkers: selecting the right drug for the right patient.

Authors:  Gary J Kelloff; Caroline C Sigman
Journal:  Nat Rev Drug Discov       Date:  2012-02-10       Impact factor: 84.694

5.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

Review 6.  Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.

Authors:  Evette S Radisky; Derek C Radisky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-05       Impact factor: 2.673

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 8.  Stromal induction of breast cancer: inflammation and invasion.

Authors:  Evette S Radisky; Derek C Radisky
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

9.  The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Authors:  Scott A Tomlins; Daniel R Rhodes; Jianjun Yu; Sooryanarayana Varambally; Rohit Mehra; Sven Perner; Francesca Demichelis; Beth E Helgeson; Bharathi Laxman; David S Morris; Qi Cao; Xuhong Cao; Ove Andrén; Katja Fall; Laura Johnson; John T Wei; Rajal B Shah; Hikmat Al-Ahmadie; James A Eastham; Scott E Eggener; Samson W Fine; Kristina Hotakainen; Ulf-Håkan Stenman; Alex Tsodikov; William L Gerald; Hans Lilja; Victor E Reuter; Phillip W Kantoff; Peter T Scardino; Mark A Rubin; Anders S Bjartell; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

10.  A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.

Authors:  Tohru Nakagawa; Thomas M Kollmeyer; Bruce W Morlan; S Keith Anderson; Eric J Bergstralh; Brian J Davis; Yan W Asmann; George G Klee; Karla V Ballman; Robert B Jenkins
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240
View more
  5 in total

1.  Proteolytic activation of the human epithelial sodium channel by trypsin IV and trypsin I involves distinct cleavage sites.

Authors:  Silke Haerteis; Annabel Krappitz; Matteus Krappitz; Jane E Murphy; Marko Bertog; Bettina Krueger; Regina Nacken; Hyunjae Chung; Morley D Hollenberg; Wolfgang Knecht; Nigel W Bunnett; Christoph Korbmacher
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

2.  Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.

Authors:  Bonan Lin; Xiaomeng Zhou; Shuye Lin; Xiaoyue Wang; Meiying Zhang; Baoping Cao; Yan Dong; Shuai Yang; Ji Ming Wang; Mingzhou Guo; Jiaqiang Huang
Journal:  J Mol Med (Berl)       Date:  2017-08-26       Impact factor: 4.599

3.  Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Authors:  Devon Pendlebury; Ruiying Wang; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Benjamin J Madden; Marat D Kazanov; Evette S Radisky
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

4.  PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast.

Authors:  Li Qian; Xiangxiang Gao; Hua Huang; Shumin Lu; Yin Cai; Yu Hua; Yifei Liu; Jianguo Zhang
Journal:  Oncotarget       Date:  2017-03-28

5.  CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma.

Authors:  Shuye Lin; Hanli Xu; Mengdi Pang; Xiaomeng Zhou; Yuanming Pan; Lishu Zhang; Xin Guan; Xiaoyue Wang; Bonan Lin; Rongmeng Tian; Keqiang Chen; Xiaochen Zhang; Zijiang Yang; Fengmin Ji; Yingying Huang; Wu Wei; Wanghua Gong; Jianke Ren; Ji Ming Wang; Mingzhou Guo; Jiaqiang Huang
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.